News

The phase I component of the new study is a multi-center, multi-national trial which will first determine the dose, safety, tolerability, pharmacokinetics and preliminary efficacy of PT-523 in

The primary goal of this trial is to assess the safety and effectiveness of REN-1654 in treating acute pain in post-herpetic neuralgia (PHN) patients. “We are pleased to

Verapamil hydrochloride (HCI), a calcium channel blocker, is indicated for the management of essential hypertension. Par expects to begin shipment of the product in early 2005 and, based

The transaction significantly expands Valeant’s business in North America and enhances the company’s neurology franchise through the acquisition of key products and a specialized neurology sales organization. The

The FDA has determined that Ranbaxy’s formulation can be expected to have the same therapeutic effect as an equivalent dose of Biaxin XL filmtab extended release tablets 500mg

Pfizer said that it vigorously refutes claims by Public Citizen that safety data from a 1999 Celebrex study in Alzheimer’s patients were “undisclosed.” The study, Pfizer explained, was

Nastech developed Nascobal nasal spray (Cyanocobalamin, USP) as an alternative to Nascobal gel for intranasal administration, an FDA approved product launched in 1997. Worldwide marketing rights to both

The findings were from an ongoing phase II National Cancer Institute-sponsored study and final results from a phase II investigator initiated study examining the potential role of Velcade

Both companies will now share US development costs and future net profits, if any, derived from sales in the US of a resultant therapeutic product candidate for the